Metronidazole Noridem

Metronidazole, the active ingredient in Metronidazole Noridem, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It treats anaerobic bacterial and protozoal infections in adults and children as prescribed.

GNH USA supplies Metronidazole Noridem as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole Noridem is indicated for several anaerobic and protozoal infections across different organ systems. - Bacterial vaginosis: eradicates the anaerobic bacteria responsible, reducing symptoms and recurrence. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving infection signs. - Anaerobic bacterial infections: provides bactericidal activity against susceptible anaerobes, aiding resolution of infection. - Intra‑abdominal infections: treats mixed aerobic‑anaerobic infections in the peritoneal cavity. - Pelvic inflammatory disease: targets anaerobic pathogens contributing to PID, supporting clinical improvement. - Clostridioides difficile infection (adjunctive therapy): used alongside standard therapy to reduce toxin production.

Metronidazole may cause a range of adverse reactions, most of which are dose‑related and reversible after discontinuation.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild headache episodes. - Diarrhea: loose stools without severe dehydration. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Seizures: neurologic events requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hypersensitivity reactions: anaphylaxis or severe allergic response.

Before initiating Metronidazole Noridem, consider the following precautions to ensure safe use. - Pregnancy: Category B, use only if benefits outweigh potential risks. - Breastfeeding: excreted in milk; assess infant risk before continuation. - Liver impairment: dose may need adjustment; monitor hepatic function. - Alcohol interaction: avoid alcohol due to disulfiram‑like reaction. - Renal dysfunction: monitor renal function, especially in prolonged therapy. - Store at ambient temperature: keep below 25°C, protect from light and moisture in original container.

Metronidazole can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Alcohol: causes severe flushing, tachycardia, and nausea. - Warfarin: may increase anticoagulant effect, raising bleeding risk. - Lithium: can raise lithium levels, leading to toxicity. - Cytochrome P450 inducers (e.g., rifampin, carbamazepine): markedly reduce metronidazole concentrations. - Disulfiram: additive disulfiram‑like reactions.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma levels. - Phenytoin: may enhance neurotoxic effects. - Oral contraceptives: possible reduction in efficacy; advise backup contraception. - Theophylline: may increase theophylline levels, monitor for toxicity. - Isoniazid: may increase risk of peripheral neuropathy.